List view / Grid view
24 October 2024 | By
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
16 October 2024 | By
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
